Schlueter, M., Finn, E., Díaz, S., Dilla, T., Inciarte-Mundo, J., & Fakhouri, W. (2019). Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. Clinicoecon Outcomes Res.

Schlueter, Max, Elaine Finn, Silvia Díaz, Tatiana Dilla, José Inciarte-Mundo, and Walid Fakhouri. "Cost-effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-to-severe Rheumatoid Arthritis in Spain." Clinicoecon Outcomes Res 2019.

Schlueter, Max, et al. "Cost-effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-to-severe Rheumatoid Arthritis in Spain." Clinicoecon Outcomes Res 2019.